Cambridge Investment Research Advisors’s Fidelity Blue Chip Value ETF FBCV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$826K Buy
22,961
+802
+4% +$29.6K ﹤0.01% 2343
2025
Q4
$790K Sell
22,159
-1,240
-5% -$43.4K ﹤0.01% 2302
2025
Q3
$797K Buy
23,399
+2,644
+13% +$88.4K ﹤0.01% 2241
2025
Q2
$680K Buy
20,755
+6,705
+48% +$212K ﹤0.01% 2257
2025
Q1
$449K Buy
14,050
+1
+0% +$32 ﹤0.01% 2542
2024
Q4
$444K Buy
14,049
+3,716
+36% +$122K ﹤0.01% 2526
2024
Q3
$338K Buy
10,333
+549
+6% +$17.2K ﹤0.01% 2740
2024
Q2
$294K Buy
9,784
+355
+4% +$10.8K ﹤0.01% 2718
2024
Q1
$294K Buy
9,429
+157
+2% +$4.65K ﹤0.01% 2718
2023
Q4
$271K Buy
+9,272
New +$258K ﹤0.01% 2670
2023
Q3
Sell
-9,929
Closed -$277K 3178
2023
Q2
$277K Sell
9,929
-1,587
-14% -$43.7K ﹤0.01% 2601
2023
Q1
$314K Buy
+11,516
New +$321K ﹤0.01% 2445

Other funds holding FBCV

Cambridge Investment Research Advisors's FBCV Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its Fidelity Blue Chip Value ETF (FBCV) stake by 3.6% in Q1 2026, buying an estimated $29.6K and bringing the position to 22,961 shares worth $826K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

Cambridge Investment Research Advisors first reported a position in FBCV in Q1 2023 and has held it in 12 quarters since. 43 funds tracked by Wall St. Rank hold FBCV as of Q1 2026.

  • Cambridge Investment Research Advisors held 22,961 shares of Fidelity Blue Chip Value ETF worth $826K as of Q1 2026.
  • Cambridge Investment Research Advisors bought 802 Fidelity Blue Chip Value ETF shares in Q1 2026, an estimated $29.6K.
  • Fidelity Blue Chip Value ETF made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #2343 holding.
  • Cambridge Investment Research Advisors first reported a position in Fidelity Blue Chip Value ETF in Q1 2023 and has held it in 12 quarters since.
  • 43 funds tracked by Wall St. Rank held Fidelity Blue Chip Value ETF as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.